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Acinetobacter baumannii is a gram-negative, non-motile bacterium that, due to its
multidrug resistance, has become a major nosocomial pathogen. The increasing
number of multidrug resistant (MDR) strains has renewed interest in phage therapy.
The aim of our study was to assess the effectiveness of phage administration in
Acinetobacter baumannii wound infections in an animal model to demonstrate phage
therapy as non-toxic, safe and alternative antibacterial remedy. Using classical methods
for the study of bacteriophage properties, we characterized phage vB-GEC_Ab-M-G7
as a dsDNA myovirus with a 90 kb genome size. Important characteristics of vB-
GEC_Ab-M-G7include a short latent period and large burst size, wide host range,
resistance to chloroform and thermal and pH stability. In a rat wound model, phage
application effectively decreased the number of bacteria isolated from the wounds of
successfully treated animals. This study highlights the effectiveness of the phage therapy
and provides further insight into treating infections caused by MDR strains using phage
administration.
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INTRODUCTION
Acinetobacter baumannii is a gram-negative, non-motile bacterium that has become a major
nosocomial pathogen due to its multidrug resistance. A. baumanni strains have been isolated which
are resistant to almost all antibiotics, including a high prevalence of resistance to carbapenems
which has been reported worldwide since the 1990’s (Kempf and Rolain, 2012; Ahmed et al.,
2016; Nowak and Paluchowska, 2016). Most of the strains are still sensitive in vitro to colistin,
an antibiotic which was considered toxic for a long time (Montero et al., 2004). Recent studies
suggest it can actually be used as an efficient antimicrobial agent (Michalopoulos and Falagas,
2011). But colistin resistant A. baumannii strains have already been reported (Lopez-Rojas et al.,
2011; Kempf and Rolain, 2012; Gupta et al., 2016; Yilmaz et al., 2016). Currently there is no remedy
to effectively remove A. baumannii from the hospital environment, as this microbe is resistant
to dehydration, chemical sanitizers and detergents (Yang et al., 2010). As a result, the risk of
A. baumannii nosocomial infection is increasing.
The worldwide spread of MDR strains of a number of different pathogens has renewed interest
in bacteriophage therapy. Bacteriophages are viruses which infect and lyse bacteria. Lytic phages for
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the treatment of infections were first introduced by Felix
d’Herelle in 1920 (Matsuzaki et al., 2005). Due to their
observed efficacy and recognized specificity, phages have been
used as a treatment modality in the Formers Soviet Union
and Eastern Europe, especially in Georgia, for decades; much
successful work was also carried out in France and elsewhere
(Matsuzaki et al., 2005; Sulakvelidze, 2005; Kutter et al.,
2010).
The study of phage therapy in animal models is an
essential bridge between in vitro and clinical studies. Mice with
artificial burns, pneumonia, pulmonary infections with various
microbes (Pseudomonas spp., Staphylococcuss spp., Enterococcuss
spp., Klebsiella pneumoniae, Escherichia coli) were successfully
treated with phages (Biswas et al., 2002; Chibani-Chennoufi
et al., 2004; Vinodkumar et al., 2005; McVay et al., 2007;
Debarbieux et al., 2010; Morello et al., 2011). Although several
A. baumannii phages have been isolated and characterized
in terms of potential therapeutic application (Soothill, 1992;
Yang et al., 2010; Popova et al., 2012), a very few in vivo
trials for A. baumannii phages have been reported: Wang
et al. (2016), showed successfully use of phage intranasal
application for treatment pneumonia on mice model. All mice
survived after intranasal application of phages published by
Jeon et al. (2016) as well. Uncontrolled diabetic rats were
used for infected wound modeling for study phage therapy
effectiveness by Shivaswamy et al. (2015), where ones more
was demonstrated A. baumannii phage prospects for treatment
of MDR bacteria caused infections. Several studies done in
Georgia at Eliava Institute of BMV highlight phage therapy
advantages and effectiveness, as well (Kutateladze and Adamia,
2008, 2010). Furthermore, a range of phages targeting the
organism in question are required to successfully develop a
phage therapy approach. In our study we have characterized
a promising new lytic A. baumannii bacteriophage vB_Ab-M-
G7 and report its potential in phage therapy on a rat wound




Clinical isolates of Acinetobacter baumannii G7 and T-10
were used in this study. A. baumannii strains G7 –isolated
in Georgia from an injured soldier during the Georgian–
Russian War in 2008 as previously described (Kusradze
et al., 2011), was used for isolation and concentration of
the reported phage. Strain T-10 was isolated from a patient
in the hospital de la Timone, Marseille, France. Bacteria
were grown at 37◦C in Brain Heart Infusion broth and
agar, and in Herellea Agar (Jawad et al., 1994). Matrix-
assisted Laser Desorption Time-of-Flight Mass Spectrometry
(MALDI-TOF MS) (Autoflex, Bruker Daltonics) with the
flex control software (Bruker Daltonics) was used for
identification these strains. A score value >1.9 is considered




Bacteriophage was isolated from sewage water. After overnight
incubation of the sewage samples with microbial culture in Brain
Heart Infusion Broth (BHIB) at 37◦C, samples were centrifuged
at 5000 g for 20 min and filtrated and the supernatant was
checked for phages by a standard spot test: overnight host strain
(18–24 h.) diluted in BHIB 108 cfu ml−1 were streaked onto
a Petri plate with 1.5% agar. After drying of the lines (15–
20 min), 0.05 ml of each supernatant was spotted onto each
line. Plates were incubated at 37◦C for 18 h. After incubation,
the appearance of lysis zones on the bacterial lines shows the
presence of phages (Garbe et al., 2010; Karumidze et al., 2013).
Phage concentration and plaque morphology was determined
by serial dilution of the phage lysate, 1 ml serial diluted phage
and 0, 1 ml indicator bacteria was added to 4.5 ml 46◦C
0.7% soft-agar and poured onto the 1, 5% bottom agar on
Petri dishes. After 30 min the plate was incubated at 37◦C.
The results were counted after 18–24 h. Plaque Purification of
bacteriophage was repeated 15–20 times. Purified phage was
amplified and titer in the filtrate was assessed by using the double-
agar layer method (Lin et al., 2010). The phage lysate was stored
at 4◦C.
Phage Host Range Spectrum, Single
Step Growth Curve, Adsorption Rate
The phage host range spectrum was determined on 200
A. baumannii strains (Eliava Collection) using a standard spot
test protocol (Garbe et al., 2010; Karumidze et al., 2013). To
determine phage growth characteristics (latent period, burst
size), experiments were carried out according to the previously
described (Drulis-Kawa et al., 2011; Rigvava et al., 2013), with
some modifications. A. baumannii strain was grown in 10 ml
BHIB until the exponential growth phase, 0, 1 ml phage with
titer 108 pfu ml−1 was added at a multiplicity of infection (MOI)
of 0.1. Samples were taken periodically for the determination of
phage growth parameters.
To calculate the phage adsorption rate, 1 ml bacterial
suspension (107 cfu ml−1) and 1 ml phage lysate (108 pfu ml−1)
were mixed and incubated at 37◦C. 0.1 ml samples were taken
at 0’, 5’, 7’, 10’, 15’, and 20’ min and added to 9,9 ml BHIB
and 0,4 ml chloroform. Samples were mixed well and plated
using the double agar-layer method to determine the amount of
unabsorbed phages.
pH, Chloroform and Thermal Stability
Tests
The phage preparation (1 × 1010 pfu ml−1) was incubated at
37, 50, and 70◦C for 24 h. From chloroform stability tests, 1 ml
(1 × 1010 pfu ml−1) bacteriophage was mixed with 0.4 ml
chloroform and incubated for 24 h at room temperature. For pH
stability studies, phage at 1 × 1010 pfu ml−1 was incubated at
pH 3, 5, 7, 9, and 11 for 24 h. For all three experiments samples
were taken at 5 and 24 h and the phage titer was determined
using the double-agar-layer method. BHI broth and BHI agar
were used.
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Electron Microscopy
Phage morphology was determined by transmission electron
microscopy as following: a 5 µl sample was placed onto a fresh
glow discharged pioloform coated grid; the excess sample was
removed and the grid was washed using 2 × DDW (Double
Distilled Water); 2 drops of 1% uranyl acetate were added, the
excess was immediately removed and the grid was allowed to
air dry. Samples were viewed on a JEOL JEM 1400 TEM with
an accelerating voltage of 80 kV. Images were captured using a
Megaview III digital camera with iTEM software.
Phage DNA Isolation, Restriction
Endonuclease Analysis, PFGE
Before phage DNA isolation, the phage lysate was treated
with DNAse and RNAse to remove residual bacterial
debris. Standard PCR (Polymerase chain reaction)
was used to verify the purity of the phage lysate with
universal primers (536F CAGCAGCCGCGGTAATAC, Rp2
ACGGCTACCTTGTTACGACTT) targeting the 16S rRNA
gene as previously described (Bittar et al., 2008). Phage DNA
isolation was performed by using High Pure Viral Nucleic Acid
Qiagen Kit (QIAGEN, Courtaboeuf, France) according to the
manufacturer’s instructions. For digestion of phage DNA 8
different restriction endonucleases (BamHI, EcoR I, EcoRV,
HindIII, HincII, PstI, DpnI, SpeI) were used according to the
instructions provided by manufacturer. For separation of the
DNA fragments, electrophoresis was done using 0.8% agarose
gel. Restriction digestions were repeated three times. Pulsed-field
gel electrophoresis was performed as described in Lin et al.
(2010) for determination of the phage DNA size.
Preparation for Animal Wound Model
Animal experiments were done according to the Animal Rights
Committee in Georgia, which fully recognizes the Universal
Declaration of Animal Rights.
A total of 30 adult rats weighing 200–300 g were used in this
study. Experimental wounds were done as following: each rat
was anesthetized and secured to the operating table. After being
shaved, the skin was cleaned in aseptic conditions with a 5%
iodine solution and a dorsal full-thickness 1.5 × 1.5cm surgical
wound was administered. Interrupted stitches were used to secure
a plastic cover to avoid contamination, as well as for procedures
which were performed on the animals daily.
Acinetobacter baumannii T-10 and G7 were used for infection
and phage vB-GEC_Ab-M-G7was applied as a therapeutic
remedy. A. baumannii G7 was the original host for phage vB-
GEC_Ab-M-G7, titer on this strain was 1 × 1010 pfu ml−1.
A. baumannii T-10 was chosen randomly from the strains
sensitive to phage vB-GEC_Ab-M-G7, phage titer on this strain
was 2 × 108 pfu ml−1. Phage was diluted to receive 5 × 107 pfu
ml−1.
Experimental Animal Wound Model
The 30 rats with experimental wounds were divided randomly
into six groups, each containing five rats. Group I was aseptic
wound modeling – no bacteria were added, no phage. Group
II tested phage therapy of the aseptic wound (therapeutic dose)
with 1ml phage application (5 × 107 pfu ml−1), no bacteria
were added. Group III – infected wound modeling, 1ml of
Acinetobacter baumannii T-10 5 × 108 cfu ml−1 was applied,
no phage were added. Group IV tested phage therapy of the
wound infected with 1 ml of A. baumannii T-10 (5 × 108 cfu
ml−1), 1ml of phage (5 × 107 pfu ml−1) were applied 12 h
after infection. Group V – infected wound modeling, infected
with 1 ml of Acinetobacter baumannii G7 (5 × 108 cfu ml−1),
no phage were added. Group VI -phage therapy of the infected
wound (1 ml of A. baumannii G7 5 × 108 cfu ml−1) with 1ml
phage (5 × 107 pfu ml−1) applied after 12 h from infection.
Additional, phage vB-GEC_Ab-M-G7 (for groups II, IV, and VI)
were added on the wounds every 24 h for 6 days. Samples were
taken before phage application at time points 0’ (12’), 24’, 48’,
72’, and 144’ hours using a sterile swab. 4.5 ml of BHI broth was
added to the swab tube and was first titered for bacterial count
and then was filtered (0.22 µm) and titered for phage, according
to previously stated methods. The bacterial titer was determined
using Herellea agar, to avoid contamination. At the end of the
experiment, every animal was euthanized in accordance with the
law of animal rights.
RESULTS
Bacterial Strains
Microbial strains T-10 and G7 were identified as A. baumannii
using MALDI-TOF MS, with score of 2.224 and 2.272
respectively.
Phage Properties
Phage vB-GEC_Ab-M-G7was isolated from sewage using
A. baumannii G7 as the host. Using phage purification methods,
concentration and titration, a pure, high titer (1010 pfu ml−1)
stock of A. baumannii phage was obtained, which had small
plaque morphology on Petri dishes using the double-agar-layer
method. The study of phage morphology by transmission
electron microscopy showed that the phage has an icosahedral
head, about 100 nm in diameter and a 120 nm long contractile
tail, thus belongs to Myoviridae (Matsuzaki et al., 2005)
(Figure 1). It was named vB-GEC_Ab-M-G7 (phage phi G7)
according to the scheme for the nomenclature of viruses of
bacteria (Kropinski et al., 2009).
Host range spectrum studied on 200 A. baumannii strains
showed that phage vB-GEC_Ab-M-G7was able to infect 68% of
the A. baumannii strains. The latent period of phage phi G7 was
20 min and the burst size was 120 pfu per infected cell. Most
phages (91.1%) were adsorbed within 7 min (Figure 2).
Thermal stability experiments showed that phage retained
100% activity after incubation at 37◦C and almost 90% of phages
were viable after a 24 h incubation at 50◦C (Figure 3). However,
after 24 h at 70◦C no active phages were found. Phage phi G7 was
stable after 24 h of chloroform treatment and over a pH range
of 3–11 for 5 h; by 24 h the phage titer was reduced to 103 pfu
ml−1 at pH 3, but it remained unaffected within the pH range
5–11(Figure 3).
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FIGURE 1 | Electron micrographs of phage vB_Ab-M-G7. Bar
corresponds to 100 nm.
PFGE showed that the phage DNA size was 90 kb. None
of the 8 (BamHI, EcoR I, EcoRV, HindIII, HincII, PstI, DpnI,
SpeI) restriction endonucleases used in this study digested phage
vB_Ab-M-G7, although they did digest the DNA of other phages.
Phage Therapy in Infected Animal
Wound Model
All of the Group I animals survived and no A. baumannii strains
were isolated (grown in Herellae agar) from the samples taken
from them, indicating that the wound modeling was done in
FIGURE 2 | Single step growth curve of phage vB_Ab-M-G7. The latent
phase takes average 20 min and the phage produces about 120 pfu ml−1 per
infected cell.
sterile conditions and this artificial wound did not affect the rats’
mortality.
To examine the toxicity of phage, the wounded but not
infected experimental Group II was used, where only phage vB-
GEC_Ab-M-G7was applied to the artificial wound. All of the
wounded rats survived, indicating that phage phi G7 was not
toxic. Samples taken from the animals showed no contamination
with A. baumannii and the titer of the phage was not more than
2 × 101 ± 1.7(SD) pfu ml−1 in each samples taken during the
experiments (Table 1).
In groups III and V, the animals were administered 1 ml
of A. baumannii T-10 or G7 (5 × 108 cfu ml−1). Purulent
and inflammatory processes after the second day of infection
could be easily observed and became heavier at the end
of experiment, indicating of infection and not colonization.
Wounds infected with A. baumannii G7 were observed to
be more serious and complicated, and in group V the rate
of mortality was 30%, by the fifth day of the experiment.
Microbial growth is shown in Figure 4 and Table 1. Samples
were tested for phage contamination; no phage plaques
were detected in the plated samples from animal groups
III and V.
FIGURE 3 | pH and thermal stability of phage vB_Ab-M-G7.
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TABLE 1 | Alternation of the bacterial titer in phage treated infected wounds.
Groups Rats (200–300 g) Bacterial Infection




1 ml 5 × 107 PFU ml−1 (6 days)
Results
I Aseptic wound – – – No strain was isolated
II Aseptic wound – 12 h Phi G7 No strain was isolated;
2 × 101 ± 1.7(SD)’ PFU”’ ml−1
III Infected wound A. baumannii T10 – – 8 × 106 ± 0.9(SD) CFU ml−1
increased to 9 × 107 ± 1.6(SD)
CFU ml−1
IV Infected wound A. baumannii T10 12 h Phi G7 7 × 106 ± 0.9(SD) CFU ml−1
decreased to 9 × 102 ±
1.3(SD) CFU ml−1
V Infected wound A. baumannii G7 – – 1 × 107 ± 1.8(SD) CFU ml−1
increased to 2,5 × 108 ±
2.9(SD) CFU ml−1
VI Infected wound A. baumannii G7 12 h Phi G7 1,4x107 ± 0.9(SD) CFU ml−1
decreased to 3 × 102 ±
1.9(SD) CFU ml−1
’, Standard Deviation; ”, Colony Forming Unit; ”’, Plaque Forming Unit.
FIGURE 4 | Phage therapy results in animal wound model. III group –
A. baumannii T-10 strain titer was increased from ≈8 × 106 ± 0.9 (standard
deviation – SD) cfu ml−1 to ≈ 9 − 107 ± 1.6(SD) cfu ml−1; IV group-
alternation of the bacterial and phage titer during the 7 days were as
following, ≈7 × 106 ± 0.9(SD)cfu ml−1 to ≈ 9 × 102 ± 1.3(SD) cfu ml−1;
≈6 × 105 ± 1.5(SD) pfu ml−1 to ≈ 3 × 102 ± 1.6(SD) pfu ml−1, respectively;
V group – A. baumannii G7 strain titer was increased from ≈1 × 107 ±
1.8(SD) cfu ml−1 to ≈ 2.5 × 108 ± 2.9(SD) cfu ml−1; VI group- alternation of
the bacterial and phage titer during the 7 days were as following,
≈1.4 × 107 ± 0.9(SD) cfu ml−1 to ≈3 × 102 ± 1.9(SD) cfu ml−1;
≈7 × 105 ± 1.5(SD) pfu ml−1 to ≈2 × 102 ± 1.9(SD) pfu ml−1, respectively.
Phage and bacteria titer is given in arithmetical average.
Group VI – 12 h after infection with 1ml of A. baumannii G7
(5 × 108 cfu ml−1), 1 ml of 5 × 107 pfu ml−1 phage phi G7
was applied to the wound during 6 days. During treatment the
rats were active and some of them were aggressive. Before the
phage application no inflammatory processes were present. By
the third, day purulent processes appeared which fully vanished
by the end of the experiment. The reduction of the infection
symptoms was correlated with decreasing of the bacteria titer
to an average 3 × 102 ± 1.9(SD) cfu ml−1and the phage titer
dropped from 7 × 105 ± 1.5(SD) 2 × 102 ± 1.9(SD) pfu ml−1
(Figure 4, Table 1). All the animals survived.
Group IV -A. baumannii T-10 showed less virulence than
A. baumannii G7, (groups III and V). Slight inflammations, as
well as a little purulence were characteristics of the treatment
processes, but it fully disappeared before days 5 and 6. Decreasing
of the bacterial and phage titer, respectively, are given in Figure 4
and Table 1.
DISCUSSION
Due to the increase in the number of antibiotic resistant
microbes, phage therapy is considered as alternative treatment
for MDR bacterial infections (Chibani-Chennoufi et al., 2004;
Sulakvelidze, 2005; Debarbieux et al., 2010; Kutter et al., 2010).
Phage preparations are widely used to treat infections caused by
E. coli, Pseudomonas aeruginosa, Salmonella spp., Enterococcus
faecium, Streptococcus spp., Staphylococcus aureus and Proteus
spp. in countries of the former Soviet Union (Matsuzaki et al.,
2005; Sulakvelidze, 2005), but A. baumannii phages have not
yet been used as therapeutic tools. In our study we have shown
effectiveness of the phage vB-GEC_Ab-M-G7in vivo, correlated
with its high in vitro activity.
Phage phi G7 is a tailed virus with 90kb double stranded
DNA genomes, belonging to the Myoviridae family. Some
characteristics of phage phi G7 are: a short latent period and
large burst size, quite wide host range (68% on 200 clinical
strains), resistant to chloroform and stabile in different thermal
and pH ranges. Resistance to different restriction enzymes
presumably helps make this phage active over such a wide
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spectrum; sequencing of the phage will determine whether
this involves selection against all such restriction sites, as was
observed for staph phage SB-1 (Kvachadze et al., 2011) or some
other mechanism, such as the substitution of an unusual base
seen in coliphage T4 and its relatives (Miller et al., 2003). All
these characteristics help made phage phi G7 a very promising
component of a cocktail for treatment of A. baumannii infection.
For this in vivo study we selected two A. baumannii strains: G7
and T-10 that were correctly identified as A. baumannii using
MALDI-TOF MS. Patient-delivered A. baumannii G7 is the host
for phage phi G7 and strain T-10 was chosen randomly from
phi G7 sensitive strains for this experiment. No phage phi G7
adaptation procedures were carried out using the A. baumannii
T-10 strain. We wanted to show the effectiveness of the phage phi
G7 therapy in an artificial infected rats wound model and at the
same time to investigate potential differences in the therapeutic
effectiveness of this phage, for treatment of infections caused by
both host and randomly selected A. baumannii strains.
We have demonstrated in this animal wound model that
the phage application did not have a toxic effect on wounded
rats: in phage control group (group II) where phages were
administered to the wound all the rats survived, they were
feeling calm and no aggression was observed. Phage application
in wound infections caused by A. baumannii T-10 and G7
effectively reduced the number of bacteria isolated from treated
animals and all visible infection symptoms (red, swollen-purulent
wound) disappeared (Figure 4, Table 1). Aggressive behavior
of the infected rats fully vanished which was correlated with
disappearing of infection symptoms. Rats with infections caused
by the original host strain and by a randomly selected strain
were treated with the same successful results. Obviously more
detailed studies examining the effect of the phage dosage,
timing of phage administration, pharmacokinetics will need to
be undertaken before A. baumannii phages can be used in
therapy. However, our characterization of phage vB-GEC_Ab-M-
G7and animal experimentation illustrates its big potential for
treatment of infections. We hope this study will provide further
insight on treating infections caused by MDR strains using phage
administration.
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